S'abonner

Risk analysis of early childhood eczema - 15/08/11

Doi : 10.1016/j.jaci.2009.03.046 
Hans Bisgaard, MD, DMSci a, , Liselotte B. Halkjær, MD, PhD a, Rikke Hinge, MD a, Charlotte Giwercman, MD a, Colin Palmer, PhD b, Lori Silveira, MSc c, Matthew Strand, PhD c
a Copenhagen Prospective Studies on Asthma in Childhood, Danish Pediatric Asthma Center, Health Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark 
b Population Pharmacogenetics Group, Biomedical Research Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom 
c Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, Colo 

Reprint requests: Hans Bisgaard, MD, DMSci, Professor of Pediatrics, Copenhagen Prospective Studies on Asthma in Childhood, Danish Pediatric Asthma Center, Health Sciences, University of Copenhagen, Copenhagen University Hospital, Gentofte, Ledreborg Alle 34, 2800 Gentofte, Copenhagen, Denmark.

Abstract

Background

The increasing prevalence of eczema suggests the role of environmental factors triggering a genetic predisposition.

Objective

To analyze the effect of environmental exposures in early life and genetic predisposition on the development of eczema before age 3 years.

Methods

The Copenhagen Study on Asthma in Childhood is a prospective clinical study of a birth cohort of 411 children born of mothers with asthma. Eczema was diagnosed, treated, and monitored at the clinical research unit, and complete follow-up for the first 3 years of life was available for 356 children. Risk assessments included filaggrin loss-of-function mutation; parent’s atopic disease; sex; social status; previous deliveries; third trimester complications and exposures; anthropometrics at birth; month of birth; duration solely breast-fed; introduction of egg, cow’s milk, and fish; time spent in day care; cat and dog at home; feather pillow; nicotine in infant’s hair; and temperature and humidity in bedroom.

Results

Eczema developed in 43.5% of the infants. Filaggrin mutation (odds ratio [OR], 3.20; 95% CI, 1.46-7.02; P = .004), mother’s eczema (OR, 2.80; 95% CI, 1.70-4.63; P < .0001), and father’s allergic rhinitis (OR, 1.91; 95% CI, 1.09-3.33; P = .02) were directly associated with risk of eczema. Risk of eczema was significantly reduced by birth length (OR per cm increase, 0.87; 95% CI, 0.78-0.97; P = .02), increased bedroom temperature (probably inverse causality; OR, 0.80; 95% CI, 0.66-0.97; P = .02), and dog living in the home (OR, 0.44; 95% CI, 0.23-0.87; P = .02).

Conclusions

Dog exposure reduced the risk of eczema, whereas short length at birth, filaggrin mutation, and parental atopy increased the risk of eczema by age 3 years.

Le texte complet de cet article est disponible en PDF.

Key words : Length at birth, breast-feeding, dog, eczema, filaggrin, risk factor

Abbreviations used : COPSAC, FLG, OR


Plan


 Supported by the Lundbeck Foundation, the Pharmacy Foundation of 1991, the Danish Medical Research Council, the Danish Pediatric Asthma Center, the Danish Lung Association, the Hans Skoubys og hustru Emma Skoubys Fond, and Oda Pedersens Legat.
 Disclosure of potential conflict of interest: H. Bisgaard has been a consultant to and paid lecturer for and holds sponsored grants from Aerocrine, AstraZeneca, Altana, GSK, Merck, MedImmune, NeoLab, and Pfizer; in addition, he is a lecturer for AstraZeneca and Merck, receives grant support from AstraZeneca, Merck, MedImmune, and GSK, and has provided expert witness testimony/legal consultation services to NeoLab. The Danish Pediatric Asthma Center has received unrestricted institutional grants from Aerocrine, AstraZeneca, GSK, Merck, and MedImmune. The rest of the authors have declared that they have no conflict of interest.
 COPSAC is funded by private and public research funds; see www.copsac.com. Grants above 100.000 Euro were donated by the Lundbeck Foundation, the Pharmacy Foundation of 1991, the Augustinus Foundation, the Danish Medical Research Council, and the Danish Pediatric Asthma Centre. The funding agencies did not have any role in study design, data collection and analysis, decision to publish, or preparation of the article.


© 2009  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 123 - N° 6

P. 1355 - juin 2009 Retour au numéro
Article précédent Article précédent
  • Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis
  • Philippe-Jean Bousquet, Christophe Combescure, Jean-Michel Klossek, Jean-Pierre Daurès, Jean Bousquet
| Article suivant Article suivant
  • Meta-analysis of filaggrin polymorphisms in eczema and asthma: Robust risk factors in atopic disease
  • Elke Rodríguez, Hansjörg Baurecht, Esther Herberich, Stefan Wagenpfeil, Sara J. Brown, Heather J. Cordell, Alan D. Irvine, Stephan Weidinger

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.